Auph short interest.

Still, when we talk about a small-cap biotech that is clearly drawing the interest of some big pharma guys, we can say that AUPH's current valuation is very low, without but surely with buyout ...Nov 17, 2023 · Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Down 16.4% in August marketbeat.com - September 17 at 6:15 AM: Here's Why We're Not At All Concerned With Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn Situation finance.yahoo.com - September 11 at 9:56 AM Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ:AUPH) plunged 14% after the company announced Thursday three new executive hires, including a new R&D chief, likely cooling speculation that the company may be acquired.Aurinia also disclosed that its chief commercial officer will be leaving next …@PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ...

Live Short Interest data, Utilization, Cost to borrow and much more for Aurinia Pharmaceuticals Inc., Nasdaq:AUPHIt seems like the purpose of the document is to formalize the recent changes to the commercial partnership (originally announced here) as well as some of the items from the cooperation agreement released in February; particularly when it comes to the availability of stock warrants that Healios can execute once they achieve approvals for ARDS ...

Short term loan lenders offer loans based on current income or assets and not one’s credit score. Because of this many people choose to get a short title loan when they’re in need of money.

Aug 2, 2023 · Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus... Short Interest. Percentage of Shares Shorted 6.91% of the float of ESSA Pharma has been sold short. Short Interest Ratio / Days to Cover ESSA Pharma has a short interest ratio ("days to cover") of 7.8. Change versus previous month Short interest in ESSA Pharma has recently increased by 1.47%, indicating that investor sentiment is …WebShort interest, stock short squeeze, short interest ratio & short selling data positions for NASDAQ, NYSE & AMEX stocks to find shorts in the stock market.WebAurinia Pharma press release (NASDAQ:AUPH): Q3 GAAP EPS of -$0.09 beats by $0.08.; Revenue of $54.52M (-2.3% Y/Y) beats by $16.02M. Achieved European pricing and reimbursement milestone triggering ...Aurinia Pharmaceuticals last released its quarterly earnings results on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. The business earned $54.52 million during the quarter, compared to the consensus estimate of $38.41 million.

MKT Capital, which owns 4.2% of the outstanding shares of Aurinia Pharmaceuticals ( NASDAQ: AUPH ), is calling on the company to put itself up for sale. In a Monday letter to shareholders, MKT ...

The SPDR S&P Biotech ETF, one of the largest U.S. biotech ETFs, has a short interest percent of float of 57.7%, according to data from S3 Partners.

Historical equity short-Interest data for all listed tickers starting 2018 ... AUPH (Aurinia Pharmaceuticals Inc) Start Date:2013-11-08. AUR (Aurora Innovation ...Get the latest SCYNEXIS Inc (SCYX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.The settlement with Sun Pharma appeared to spark some renewed speculation that the company could be a takeover target again. Dealreporter speculated at the time that Aurinia (AUPH) could be viewed as a takeout candidate with the patent overhang lifted. Aurinia (AUPH) short interest is 10.7%.Market Capitalization. $1.24 billion. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $14.00. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media.Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...

Aurinia Pharmaceuticals AUPH closed the last trading session at $9.04, gaining 22.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.21 indicates a 46.1% upside potential. The average comprises seven short-term …As of November 15th, there was short interest totaling 2,500 shares, a decline of 56.1% from the October 31st total of 5,700 shares. Based on an average trading volume of 18,700 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company's stock are sold short. View Anebulo Pharmaceuticals' Short Interest.Aurinia Pharma press release (NASDAQ:AUPH): Q3 GAAP EPS of -$0.09 beats by $0.08.; Revenue of $54.52M (-2.3% Y/Y) beats by $16.02M. Achieved European pricing and reimbursement milestone triggering ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ...Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...AUPH / Aurinia Pharmaceuticals Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:AUPH to the lender of that security. This fee is shown as an annual percentage rate (APR).Aug 24, 2022 · Approximately 10% of the overall float is currently held short. Two directors bought a collective 10,000 shares in early March. Prior to that several insiders sold just over $1.2 million worth of ...

AUPH has hovered mostly in the $13's and with a few short lived high's in the $14's and $15's. Has had some pretty volatile swings in single day trading periods.

TRKA Update - Nothing has changed with TRKA still sitting at well over 120% short interest. When in doubt just zoom out. This drop is expected after the last run-ups and the heavy shorting. Don't let them scare you off they are …Aurinia Pharmaceuticals ( NASDAQ: AUPH) soared 6.7% amid takeover speculation. The Aurinia ( AUPH) stock surge comes amid a report that a Gilead Sciences ( GILD) corporate jet made a trip to ...According to the issued ratings of 2 analysts in the last year, the consensus rating for Aurinia Pharmaceuticals stock is Buy based on the current 2 buy ratings for AUPH. The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00.Get the latest Aurinia Pharmaceuticals Inc (AUPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Aurinia Pharmaceuticals (AUPH, $9.25) price may drop as it broke higher Bollinger Band on Nov 20, 2023 Tickeron - Technical Analysis • 6 days ago. This price move could be a signal that AUPH may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options... Despite upbeat remarks from its chief executive ahead of the earnings, Aurinia’s (NASDAQ:AUPH) 2022 sales guidance fell short of expectations as net revenue for the year dropped ~9% YoY to $45 ...1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc. Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to which investors are betting on the decline of Aurinia Pharmaceuticals's stock. Short interest data is...AUPH Short Positions, Funds Shorting Aurinia Pharmaceuticals Inc ... Short Interest Funds Shorting AUPH Short Transactions Short Volume Fails to Deliver. Options . Options Chain Options Sentiment Options Flow Gamma Exposure Implied Volatility. Filings . SEC Filings - Categorized SEC Filings - Latest Press Releases Exhibits. Financials .

Jan 5, 2023 · AUPH has multiple downside risks that investors need to consider when managing their position. First, Aurinia is still recording losses and reported a net loss of $82.1M for the first three ...

Dec 1, 2023 · The company has $337.90 million in cash and $93.21 million in debt, giving a net cash position of $244.69 million or $1.70 per share. Cash & Cash Equivalents.

To find anything from restaurants to clothing stores and auto repair shops in your area, just search Yelp.com. Though Yelp features information for businesses all around the world, you can narrow your search results down to a radius as shor...Short Interest. Prev. Close. Compare to Peers. More on AUPH. Trending Analysis. Trending News. Seeking Alpha - Power to Investors. Power to Investors. Follow us. Download app. Subscription Support ...Aurora Cannabis Inc. ACB-T. 10.7%. $29.6. 10.6%. On the 20 most shorted companies by percentage of float table, Canada Goose Holdings Inc. ( GOOS-T) is once again perched at the top, with 32.6 per ...WebSep 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ... 1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc. MKT Capital, which owns 4.2% of the outstanding shares of Aurinia Pharmaceuticals ( NASDAQ: AUPH ), is calling on the company to put itself up for sale. In a Monday letter to shareholders, MKT ...Feb 28, 2022 · For 2022, Aurinia ( AUPH) projects net revenue from sales of Lupkynis to reach $115M-135M. Several days ago, shares of the company surged in reaction to upbeat remarks made by CEO on its sales ... Short Interest: 17.28M (10/31/23)Short Interest Change-0.88%: Percent of Float: 13.23%HRTX 1.3100 (+20.18%) Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars.

Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...Jul 18, 2023 · Learn more about AUPH stock here. Skip to content. Explore Alpha Picks; ... Interest income rose to $3.8 million due to higher yields from increased interest rates. ... cash equivalents, and short ... AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...Instagram:https://instagram. has the stock market bottomed outplatinum stockbud light stcknovatech stock where to buy Aurinia Pharmaceuticals Stock (NASDAQ: AUPH) stock price, news, charts, stock research, profile. ... Profile News Analyst Ratings Guidance Dividends Earnings Insider Trades Ideas Short Interest. 0. best home loan companies for veteranshow do you trade forex Jan 4, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) rose 5% amid speculation the company may be a takeover target after Tuesday's patent settlement with Sun Pharmaceuticals. Aurinia ( AUPH) surged 38% on ... Which Aurinia Pharmaceuticals insiders have been selling company stock? The following insiders have sold AUPH shares in the last 24 months: David R.W. Jayne ($98,333.58), Joseph M Miller ($100,986.24), Joseph P Hagan ($2,877.76), Peter Greenleaf ($292,785.00), and Stephen P Robertson ($173,453.88). How much insider selling is … dread mar tickets AUPH - Aurinia Pharmaceuticals Inc. Advanced Chart, Quote and financial news from the leading provider and award-winning BigCharts.com.WebPrincipal Financial Group Inc. cut its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 8.4% in the 2nd quarter, according to its most recent filing with the ...Aurinia Pharmaceuticals AUPH closed the last trading session at $9.04, gaining 22.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.21 indicates a 46.1% upside potential. The average comprises seven short-term …